Diabetic Neuropathy Pain Management: A Global Challenge

Qureshi, Zunaira; Ali, Murtaza Najabat

doi:10.2174/1573399816666201103142521

Cited by 8 publications

(6 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Diabetes mellitus was reported among the exclusion criteria from this retrospective study. Diabetes mellitus is an endocrine disease with documented evidence of interference in nerve sensitivity and transmission that takes the name of diabetic neuropathy [ 32 ]. As far as the oral cavity is concerned, a worsening of the quality of life in healing after tooth extraction is documented in patients with diabetes, and some authors suggest a correlation between third molar pathology and diabetes mellitus in some patients [ 33 , 34 , 35 ].…”

Section: Discussionmentioning

confidence: 99%

Patterns of Third-Molar-Pericoronitis-Related Pain: A Morphometrical Observational Retrospective Study

et al. 2023

View full text Add to dashboard Cite

Background: Mandibular third molar (M3M) removal and the management of postoperative complications represent a common matter of interest in oral and maxillofacial surgery. Pain represents a great symptom for patients affected by pericoronitis and it is the most common indication for third molar removal. The aim of the present article is to search for patterns of pre-operative pain in patients before undergoing third molar surgery and to test for a relation between some patterns of symptoms, such as pain intensity, site of symptomatic tooth, and referred area of pain. Methods: This retrospective observational study enrolled a total of 86 patients, aged (mean ± SD) 34.54 ± 13.62 years (range 17–78 years), scheduled for outpatient third molar extraction at the Oral Surgery School, Department of Medical Biotechnologies, Policlinico “Le Scotte”, University of Siena. Pericoronitis and pain were the symptoms of the patients and the indication of extraction. Inclusion criteria were the presence of partially impacted third molars, confirmed with a preoperative panoramic radiograph, and preoperative pain. Exclusion criteria were known neurological disease (such as previous trigeminal or facial nerve injuries), impaired communicative or cognitive disease, diagnosed diabetes mellitus, and oral surgical intervention within 30 days before data collection. Patients were visited and asked to answer a morphometric analytic questionnaire about their perception of pain referred to the third molar. Analyses were performed on statistical evaluation on age, age ranges, patient gender, prior third molar extraction, site of pericoronitis, pain score (1–10), and pain area. Two-tailed p values of less than 0.05 were considered significant if not otherwise specified. Results: No correlations were found between age, gender, previous extraction, tooth site (maxillar on mandible), pain score, and pain area. Patterns of third molar pericoronitis pain among 86 patients were reported. A significant correlation was found between pain score and pain area (p = 0.0111, rs = 0.3131). Conclusions: Pain intensity has indeed some kind of responsibility in determining the orofacial distribution of pain. The pain area referral patterns of the present article could be considered as a pain model resulting from the pericoronitis of maxillar and mandibular third molars.

show abstract

Section: Discussionmentioning

confidence: 99%

Patterns of Third-Molar-Pericoronitis-Related Pain: A Morphometrical Observational Retrospective Study

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Multiple drugs are used in systemic treatment and management, but there are a few drugs for the local management of PDN. The anticonvulsants, antidepressants, and opioids recommended for PDN are given as systemic therapies [ 14 , 15 ]. These drugs are administered orally which provides temporary relief from pain but exhibits adverse side effects, e.g., dizziness, dry mouth, and muscle weakness [ 16 ].…”

Section: Systemic/localized/topical Treatmentsmentioning

confidence: 99%

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

Qureshi

Ali

Khalid

2022

Journal of Diabetes Research

Self Cite

View full text Add to dashboard Cite

Diabetes is the 4th most common disease affecting the world’s population. It is accompanied by many complications that deteriorate the quality of life. Painful diabetic neuropathy (PDN) is one of the debilitating consequences of diabetes that effects one-third of diabetic patients. Unfortunately, there is no internationally recommended drug that directly hinders the pathological mechanisms that result in painful diabetic neuropathy. Clinical studies have shown that anticonvulsant and antidepressant therapies have proven fruitful in management of pain associated with PDN. Currently, the FDA approved medications for painful diabetic neuropathies include duloxetine, pregabalin, tapentadol extended release, and capsaicin (for foot PDN only). The FDA has also approved the use of spinal cord stimulation system for the treatment of diabetic neuropathy pain. The drugs recommended by other regulatory bodies include gabapentin, amitriptyline, dextromethorphan, tramadol, venlafaxine, sodium valproate, and 5 % lidocaine patch. These drugs are only partially effective and have adverse effects associated with their use. Treating painful symptoms in diabetic patient can be frustrating not only for the patients but also for health care workers, so additional clinical trials for novel and conventional treatments are required to devise more effective treatment for PDN with minimal side effects. This review gives an insight on the pathways involved in the pathogenesis of PDN and the potential pharmacotherapeutic agents. This will be followed by an overview on the FDA-approved drugs for PDN and commercially available topical analgesic and their effects on painful diabetic neuropathies.

show abstract

“…Similar to the central nervous system (CNS), the PNS is comprised of 12 cranial nerves and 31 pairs of spinal nerves. The PNS is composed of neurons and supporting glial cells (Schwann cells) ( Selvarajah, Wilkinson, Griffiths, Emery, & Tesfaye, 2008 ; Qureshi & Ali, 2021 ). Commonly, efferent axons from motor neurons transport information from the CNS to muscles and glands.…”

Section: Pathogenesis Of Diabetic Neuropathy Painmentioning

confidence: 99%

New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors

et al. 2022

View full text Add to dashboard Cite

Pre-diabetes and diabetes are growing threats to the modern world. Diabetes mellitus (DM) is associated with comorbidities such as hypertension (83.40%), obesity (90.49%), and dyslipidemia (93.43%), creating a substantial burden on patients and society. Reductive and oxidative (Redox) stress level imbalance and inflammation play an important role in DM progression. Various therapeutics have been investigated to treat these neuronal complications. Melatonin and dipeptidyl peptidase IV inhibitors (DPP-4i) are known to possess powerful antioxidant and anti-inflammatory properties and have garnered significant attention in the recent years. In this present review article, we have reviewed the recently published reports on the therapeutic efficiency of melatonin and DPP-4i in the treatment of DM. We summarized the efficacy of melatonin and DPP-4i in DM and associated complications of diabetic neuropathy (DNP) and neuropathic pain. Furthermore, we discussed the mechanisms of action and their efficacy in the alleviation of oxidative stress in DM.

show abstract

Diabetic Neuropathy Pain Management: A Global Challenge

Cited by 8 publications

References 0 publications

Patterns of Third-Molar-Pericoronitis-Related Pain: A Morphometrical Observational Retrospective Study

Patterns of Third-Molar-Pericoronitis-Related Pain: A Morphometrical Observational Retrospective Study

An Insight into Potential Pharmacotherapeutic Agents for Painful Diabetic Neuropathy

New Advances on Pathophysiology of Diabetes Neuropathy and Pain Management: Potential Role of Melatonin and DPP-4 Inhibitors

Contact Info

Product

Resources

About